Key Points
- General Counsel Russell Schundler sold 13,692 shares on April 13 at an average price of $38.37 for $525,362.04 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholdings, leaving him with 610,532 shares (a 2.19% reduction).
- The sale is part of broader insider selling across April 9–13 — including a 133,789‑share sale by CFO Michael Kaseta and multi‑date sales by the CEO and other officers — which, while reported as tax‑related 10b5‑1 trades, may create negative investor perception.
- Operationally, Liquidia recently posted an earnings beat (EPS $0.15 vs. $0.08; revenue $92.02M), has strong analyst support with a consensus "Moderate Buy" and an average price target around $43.44, and institutional ownership of roughly 64.5%.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Sarah Krepp sold 4,557 shares of Liquidia stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $38.37, for a total value of $174,852.09. Following the completion of the sale, the insider owned 147,019 shares in the company, valued at approximately $5,641,119.03. This represents a 3.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Liquidia Price Performance
Shares of LQDA stock opened at $38.71 on Wednesday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $46.67. The firm has a market cap of $3.41 billion, a P/E ratio of -46.64 and a beta of 0.45. The business's 50 day moving average price is $36.71 and its 200-day moving average price is $33.03.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The company had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. The firm's quarterly revenue was up 3072.4% compared to the same quarter last year. On average, equities research analysts anticipate that Liquidia Corporation will post -1.51 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts recently weighed in on LQDA shares. Raymond James Financial restated a "strong-buy" rating on shares of Liquidia in a research report on Thursday, March 5th. Wall Street Zen upgraded Liquidia from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. BTIG Research lifted their price target on Liquidia from $49.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Zacks Research lowered Liquidia from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 27th. Finally, Lifesci Capital upgraded Liquidia to a "strong-buy" rating in a research report on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Liquidia currently has a consensus rating of "Moderate Buy" and an average target price of $43.44.
Get Our Latest Analysis on Liquidia
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia during the fourth quarter valued at $25,000. Covestor Ltd raised its stake in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company's stock valued at $42,000 after buying an additional 359 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in Liquidia during the third quarter valued at $30,000. FNY Investment Advisers LLC purchased a new position in Liquidia during the third quarter valued at $34,000. Finally, NewEdge Advisors LLC purchased a new position in Liquidia during the second quarter valued at $25,000. Hedge funds and other institutional investors own 64.54% of the company's stock.
Trending Headlines about Liquidia
Here are the key news stories impacting Liquidia this week:
- Positive Sentiment: Liquidia last reported an earnings beat (quarter ended Mar 5) with revenue above expectations and an EPS beat, which supports near‑term fundamentals and analyst upside. Read More.
- Positive Sentiment: Several firms and analysts have reiterated or raised bullish views (Needham raised its target; Raymond James and Lifesci Capital have strong/strong‑buy ratings), contributing to an average target near $43.44 — a constructive backdrop if performance remains strong. Read More.
- Neutral Sentiment: Institutional ownership is significant (~64.5%) and some funds modestly increased positions in recent quarters — this can mute volatility from insider sales if institutions hold steady. Read More.
- Negative Sentiment: Large, concentrated insider selling disclosed across multiple filings — executives and several insiders sold shares on Apr 9–13 under 10b5‑1 plans to cover tax withholding on vested awards. The broad pattern can create negative market perception despite stated reasons. Read More.
- Negative Sentiment: Notable single transaction: CFO Michael Kaseta disclosed a 133,789‑share sale on Apr 9 (reported as a ~24.5% reduction in his position), a materially large block that may attract extra attention from investors assessing insider conviction. Read More.
- Negative Sentiment: CEO Roger Jeffs and other senior officers also executed multi‑date sales (several filings on Apr 9–13); while filed under 10b5‑1 plans and reportedly for tax obligations, repeated insider sales can nonetheless pressure sentiment near the stock’s recent highs. Read More.
Liquidia Company Profile
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
